Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 12/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TRPC5 | Q9UL62 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | TRPC4 | Q9UBN4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21499689 | 0.92 | PDE5A (0.41) | P2RX3PDE5ATP53TRPC5KCNH2 | |
| SCHEMBL18834374 | 0.92 | P2RX3 (0.38) | P2RX3PDE5ATP53TRPC5KCNH2 | |
| SCHEMBL21316298 | 0.89 | P2RX3 (0.46) | P2RX3PDE5ATP53TRPC5 | |
| SCHEMBL19505090 | 0.88 | TSHR (0.40) | P2RX3PDE5ATP53 | |
| SCHEMBL19374881 | 0.85 | P2RX3 (0.44) | P2RX3PDE5ATP53TRPC5KCNH2 | |
| SCHEMBL21499648 | 0.85 | TRPC4 (0.40) | P2RX3PDE5ATP53TRPC5KCNH2 | |
| SCHEMBL19505259 | 0.84 | P2RX3 (0.39) | P2RX3TP53TRPC5KCNH2TRPC4 | |
| SCHEMBL20431976 | 0.84 | TP53 (0.44) | P2RX3TP53 | |
| SCHEMBL21316262 | 0.84 | P2RX3 (0.41) | P2RX3PDE5ATRPC5KCNH2TRPC4 | |
| SCHEMBL21499654 | 0.84 | P2RX3 (0.40) | P2RX3PDE5ATP53TRPC5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2023-02-09 | — | — | US | disclosed |
| US-11208409-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, LLC (US) | 2021-12-28 | — | — | US | disclosed |
| US-20190322667-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | P2RX3 30/4885PDE5A 461/4885TP53 4229/4885 |
| US-11208409-B2 | Substituted xanthines and methods of use thereof | TRPC5, TRPC7, TRPC4 | P2RX3 30/4885PDE5A 461/4885TP53 4229/4885 |
| US-20190322667-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | P2RX3 30/4885PDE5A 461/4885TP53 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.